Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
SOLVD-Treatment
About the Trial
The Studies of Left Ventricular Dysfunction treatment arm randomized 2,569 patients with chronic heart failure and ejection fraction under 35 percent to enalapril or placebo. Over an average of 41 months, enalapril reduced death by 16 percent and death or hospitalization for heart failure by 26 percent. Combined with CONSENSUS, ACE inhibition became standard across the spectrum of systolic heart failure. The prevention arm showed benefit even in asymptomatic reduced ejection fraction. SOLVD gave clinicians a way to alter the natural history of heart failure, which had a 5 year survival worse than many cancers at the time.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...